Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia

Yinjun Lou; Wenbin Qian; Haitao Meng; Wenyuan Mai; Hongyan Tong; Yin Tong; Jian Huang; Jie Jin

doi:10.1002/hon.2076

journal article Aug 20, 2013

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia

Yinjun Lou Wenbin Qian Haitao Meng Wenyuan Mai Hongyan Tong

Yin Tong Jian Huang

Jie Jin

Hematological Oncology Vol. 32 No. 1 pp. 40-46 · Wiley

View at Publisher Save 10.1002/hon.2076

Topics

No keywords indexed for this article. Browse by subject →

References

32

[1]

Kakizuka "Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML" Cell (1991) 10.1016/0092-8674(91)90112-c

[2]

Sanz "Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet" Blood (2009) 10.1182/blood-2008-04-150250

[3]

Fenaux "A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group" Blood (1999) 10.1182/blood.v94.4.1192

[4]

McClellan "Treatment advances have not improved the early death rate in acute promyelocytic leukemia" Haematologica (2012) 10.3324/haematol.2011.046490

[5]

Tallman "How I treat acute promyelocytic leukemia" Blood (2009) 10.1182/blood-2009-07-216457

[6]

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

Ji Hyun Park, Baozhen Qiao, Katherine S. Panageas et al.

Blood 2011 10.1182/blood-2011-04-346437

[7]

Sanz "Modern approaches to treating acute promyelocytic leukemia" J Clin Oncol (2011) 10.1200/jco.2010.32.1067

[8]

Mi "How to manage acute promyelocytic leukemia" Leukemia (2012) 10.1038/leu.2012.57

[9]

Gore "Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia" J Clin Oncol (2010) 10.1200/jco.2009.25.5158

[10]

Powell "Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710" Blood (2010) 10.1182/blood-2010-02-269621

[11]

Ghavamzadeh "Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia" J Clin Oncol (2011) 10.1200/jco.2010.32.2107

[12]

Mathews "Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data" J Clin Oncol (2010) 10.1200/jco.2010.28.5031

[13]

Hu "Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia" Proc Natl Acad Sci USA (2009) 10.1073/pnas.0813280106

[14]

Iland "All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)" Blood (2012) 10.1182/blood-2012-02-410746

[15]

Huang "Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia" Blood (1988) 10.1182/blood.v72.2.567.567

[16]

Shen "Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients" Blood (1997) 10.1182/blood.v89.9.3354

[17]

Vardiman "The World Health Organization (WHO) classification of the myeloid neoplasms" Blood (2002) 10.1182/blood-2002-04-1199

[18]

Chen "Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia" Leukemia (1996)

[19]

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Pau Montesinos, Juan M. Bergua, Edo Vellenga et al.

Blood 2009 10.1182/blood-2008-07-168617

[20]

Chen "Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction" Oncogene (1992)

[21]

Gabert "Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program" Leukemia (2003) 10.1038/sj.leu.2403135

[22]

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Kenneth J. Kopecky et al.

Journal of Clinical Oncology 2003 10.1200/jco.2003.04.036

[23]

Sanz "Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups" Blood (2000)

[24]

Castaigne "Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia" Blood (1993) 10.1182/blood.v82.12.3560.3560

[25]

Shen "All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia" Proc Natl Acad Sci USA (2004) 10.1073/pnas.0400053101

[26]

Lehmann "Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry" Leukemia (2011) 10.1038/leu.2011.78

[27]

Lo-Coco "Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group" Blood (2010) 10.1182/blood-2010-03-276196

[28]

Sanz "Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group" Blood (2004) 10.1182/blood-2003-07-2462

[29]

Grimwade "Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy" J Clin Oncol (2009) 10.1200/jco.2008.20.1533

[30]

Chendamarai "Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy" Blood (2012) 10.1182/blood-2011-11-393264

[31]

Grimwade "Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?" Leuk Res (2011) 10.1016/j.leukres.2010.06.018

[32]

Raffoux "Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia" J Clin Oncol (2003) 10.1200/jco.2003.01.149

Metrics

11

Citations

32

References

Details

Published: Aug 20, 2013
Vol/Issue: 32(1)
Pages: 40-46
License: View

Authors

Y

Yinjun Lou